期刊文献+

前列腺特异性抗原升高首次活检阴性行重复穿刺患者阳性预测因素研究 被引量:8

Predictive factors of prostate cancer at repeat biopsy in patients with elevated serum prostate-specific antigen
原文传递
导出
摘要 目的 探讨首次前列腺穿刺活检病理结果为阴性但仍高度怀疑为前列腺癌的前列腺特异性抗原(PSA)升高患者需行重复穿刺活检的预测因素.方法 112例重复穿刺患者根据第2次活检病理结果分为前列腺癌组33例和非癌组79例.比较两组患者的临床资料并确定重复穿刺活检的阳性预测因素.结果 两组间PSA密度(PSAD)、前列腺移行区体积(TZV)和首次穿刺结果为高级别上皮内瘤变(HGPIN)比较差异有统计学意义(P<0.05).回归分析显示,PSAD和TZV是前列腺重复穿刺结果为前列腺癌的高危因素.结论 对于首次穿刺活检病理结果为阴性但PSA升高患者,PSAD和TZV可作为其接受再活检的预测因素. Objective The predictive factors of prostate cancer at repeat biopsy in patients with elevated serum total prostate specific antigen (tPSA) after initial negative biopsy.Methods A total of 112 men with suspected prostate cancer underwent prostate biopsy.All of them were diagnosed as having negative results and received the second biopsy.They were divided into a prostate cancer group (33 cases) and a non-cancer group (79 cases) according to the final pathological diagnosis from the second biopsy.We analyzed and compared the clinical characteristics of the two groups to determine the predictors for the repeat biopsy pathology results of prostate cancer.Results There were significant differences in high grade intraepithelial neoplasm (HGPIN),PSA density (PSAD) and transitional zone volume (TZV) between the two groups.The logistic regression analysis showed that PSAD and TZV had a statistically significant correlation with cancer detection.Conclusion PSAD and TZV are predictive factors of prostate cancer in patients with an initial negative biopsy of elevated PSA levels.Early repeat biopsy is especially recommended in cases with high parameters which are mentioned above.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第8期1834-1836,共3页 Chinese Journal of Experimental Surgery
关键词 前列腺特异性抗原 前列腺癌 活检 Prostate-specific antigen Prostate cancer Biopsy
  • 相关文献

参考文献6

二级参考文献26

  • 1王国民,武睿毅.我国前列腺癌实验研究的现状和展望[J].中华实验外科杂志,2005,22(9):1031-1034. 被引量:42
  • 2Gore JL, Shariat SF, Miles BJ, et al. Opti- mal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol, 2001,165(5) :1554-1559.
  • 3Jones JS, Oder M, Zippe CD. Saturation prostate biopsy with periprostatic block can be performed in office. J Urol, 2002,168 (5):2108-2110.
  • 4Jones JS, Patel A, Schoenfield L, et al. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol, 2006,175(2) :485-488.
  • 5Descazeaud A, Rubin M, Chemama S, et al. Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen. World J Urol, 2006,24(6) :676-680.
  • 6Delongchamps NB, Haas GP. Saturation biopsies for prostate cancer: Current uses and future prospects. Nat Rev Urol, 2009, 6(12) :645-652.
  • 7Patel AR, Jones JS. Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol, 2009, 19 (3): 232-237.
  • 8Zaytoun OM, Moussa AS, Gao T, et al. Office based transrectal saturation biopsy improves prostate cancer detection compared toextended biopsy in the repeat biopsy population. J Urol, 2011, 186(3) :850-854.
  • 9Scattoni V, Maccagnano C, Zanni G, et al. Is extended and sat- uration biopsy necessary? Int J Urol, 2010,17(5) :447.
  • 10Guichard G, Larr6 S, Andrea G, et al. Extended 21-Sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol, 2007,52(2) :430-435.

共引文献64

同被引文献45

  • 1Cicero G, De Luca R. Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience[J].Eur Rev Med Pharmacol Sci, 2011, 15 ( 3 ) : 325- 331.
  • 2Mantovani A. Molecular pathways linking inflammation and cancer[J]. CurrMolMed, 2010, 10 (4) : 369-373.
  • 3Xu N,Xue XY,Li XD,et al.Meperidine relieves pain during transrectal ultrasound-guided prostate biopsy.Saudi Med J,2014,35(5):454-459.
  • 4Vellekoop A,Loeb S,Folkvaljon Y,et al.Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.J Urol,2014,191(2):350-357.
  • 5Alchin DR,Murphy D,Lawrentschuk N.What are the predictive factors for gleason score upgrade following RP?Urol Int,2016,96(1):1-4.
  • 6Chung MS,Lee SH,Lee DH,et al.Is small prostate volume a predictor of Gleason score upgrading after radical prostatectomy?Yonsei Med J,2013,54(4):902-906.
  • 7Patel AR,Jones JS.Optimal biopsy strategies for the diagnosis and staging of prostate cancer.Curr Opin Urol,2009,19(3):232-237.
  • 8Hong SK,Han BK,Lee ST,et al.Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi(>or=12)-core prostate biopsy.World J Urol,2009,27(2):271-276.
  • 9Lima NG,Soares Dde F,Rhoden EL.Importance of prostatespecific antigen(PSA)as a predictive factor for concordance between the Gleason scores of prostate biopsies and radical prostatectomy specimens.Clinics(Sao Paulo),2013,68(6):820-824.
  • 10Truong M,Slezak JA,Lin CP,et al.Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.Cancer,2013,119(22):3992-4002.

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部